Fragile X Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Fragile X Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A7152
Year End sale Buy Now

 Market Overview:

The 7 major Fragile X syndrome markets reached a value of US$ 43.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 66.9 Million by 2034, exhibiting a growth rate (CAGR) of 4.07% during 2024-2034.

Report Attribute
Key Statistics
Base Year  2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 43.1 Million
Market Forecast in 2034
US$ 66.9 Million
Market Growth Rate 2024-2034
4.07%


The Fragile X syndrome market has been comprehensively analyzed in IMARC's new report titled "Fragile X Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Fragile X syndrome refers to an X-linked genetic disorder that causes a variety of intellectual disabilities, such as learning problems and cognitive impairment. This condition is caused by variations in the fragile X messenger ribonucleoprotein 1 (FMR1) gene, responsible for brain growth. Affected individuals typically have delayed speech and language development by the age of two. The disease is prominently characterized by an elongated face, flat feet, large or protruding ears, low muscle tone, larger testes, etc. In addition, patients suffering from Fragile X syndrome may experience hyperactivity, anxiety, seizures, a low intelligence quotient, aggression, irritation, sleep problems, etc. The other behavioral indications include atypical social development, memory deficits, stereotypic movements (e.g., hand flapping), limited eye contact, shyness, difficulty with face encoding, etc. This ailment is generally diagnosed by evaluating the patient's medical history and clinical presentation. The common investigations to identify the condition are genetic testing, polymerase chain reaction (PCR), and methylation status through southern blot analysis. Various other diagnostic tools may include physical and neurological exams, developmental assessments, and behavioral evaluations.

Fragile X Syndrome Market

The rising prevalence of genetic disorders on account of DNA abnormalities, gene mutations, and chromosomal damage is primarily driving the Fragile X syndrome market. Furthermore, the expanding male population, who are prone to single X chromosome gene variations, is also augmenting the market growth. Apart from this, the widespread adoption of efficient drugs, such as benzodiazepines and atypical antipsychotic agents, to target irritability and aggression by causing sedation and reducing anxiety among patients is further creating a positive outlook for the market. Additionally, the inflating application of prenatal diagnostic procedures, including amniocentesis and chorionic villus sampling, which identify the FMR1 gene mutation in the fetus and provide early diagnosis of the syndrome, is also bolstering the market growth. Moreover, the emerging popularity of speech-language and behavioral therapy, alongside pharmacological treatment, to support the management of the underlying condition is acting as another significant growth-inducing factor. In addition to this, the increasing utilization of gene therapy for delivering a functional FMR1 gene into cells using a safe and modified adeno-associated viral vector to promote the synthesis of FMR protein is expected to drive the Fragile X syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Fragile X syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Fragile X syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Fragile X syndrome market in any manner.

Recent Developments

  • In September 2023, Shionogi & Co., Ltd. reported that the United States FDA has granted Tetra Therapeutics Inc., a Rare Pediatric Disease Designation for zatolmilast (BPN14770), which is an experimental medication being evaluated for Fragile X syndrome.
  • In July 2023, Acadia Pharmaceuticals Inc. disclosed that it had expanded its existing licensing agreement with Neuren Pharmaceuticals for trofinetide to obtain ex-North American rights to the medicine as well as global rights in Fragile X syndrome to Neuren's research candidate NNZ-2591.
  • In May 2023, Allos Pharma Inc. revealed that it has met with the United States FDA to improve the design of its Phase 3 trial. This trial is intended to support a New Drug Application (NDA) for Fragile X Syndrome. Allos' investigational medication, arbaclofen, targets the molecular pathogenesis of Fragile X Syndrome and has shown significant efficacy in an FDA-approved Phase 3 trial.
  • In February 2023, KGK Science announced that it had secured an exemption under Canada's Controlled Drugs and Substances Act, beginning with its partner Nova Mentis Life Science. According to the firm, this is the first Phase IIa clinical trial research to evaluate the efficacy of repeated, oral microdosing of psilocybin as a Fragile X syndrome treatment.


Key Highlights:

  • According to the CDC, around 46% of males and 16% of females with Fragile X syndrome also have autism.
  • Fragile X syndrome often affects males more than females.
  • According to research studies, around one in every 7,000 men and one in every 11,000 women have been diagnosed with Fragile X syndrome.
  • Individuals with Fragile X syndrome are more likely to develop seizures, with rates ranging from 10% to 40% reported in the literature.
  • Based on multiple prevalence studies, it is estimated that about one million Americans carry the Fragile X premutation.


Drugs:

Zatolmilast is an investigational medicine for the treatment of Fragile X syndrome. The drug is designed to act by altering a signaling molecule called cyclic AMP (cAMP), which may enhance the maturation of connections between neurons that are deficient in individuals with Fragile X syndrome.

ZYN002 cannabidiol (CBD) gel is the first and only pharmaceutically manufactured CBD made as a patent-protected permeation-enhanced gel, and it is being tested on children with Fragile X Syndrome. ZYN002 is a transparent, permeation-enhanced gel intended to administer controlled drugs transdermally with once- or twice-daily dosing.

Acamprosate is an innovative, clinically discovered medication that functions as an NMDA receptor inhibitor and GABA receptor agonist. It is intended to treat the core social and communicative problems associated with Fragile X syndrome. The medicine aims to target vital capabilities, such as speech, thinking, social engagement, and self-care.


Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the Fragile X syndrome market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the Fragile X syndrome market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape:

This report also provides a detailed analysis of the current Fragile X syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Regulatory Status
     
Drugs Company Name
Zatolmilast Tetra Therapeutics
ZYN002 Zynerba Pharmaceuticals
NNZ-2566 ACADIA Pharmaceuticals/Neuren Pharmaceuticals
Acamprosate Confluence Pharmaceuticals


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:

Market Insights

  • How has the Fragile X syndrome market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the Fragile X syndrome market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the Fragile X syndrome market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of Fragile X syndrome across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of Fragile X syndrome by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of Fragile X syndrome by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with Fragile X syndrome across the seven major markets?
  • What is the size of the Fragile X syndrome patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of Fragile X syndrome?
  • What will be the growth rate of patients across the seven major markets?
     

Fragile X Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for Fragile X syndrome drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Fragile X syndrome market?
  • What are the key regulatory events related to the Fragile X syndrome market?
  • What is the structure of clinical trial landscape by status related to the Fragile X syndrome market?
  • What is the structure of clinical trial landscape by phase related to the Fragile X syndrome market?
  • What is the structure of clinical trial landscape by route of administration related to the Fragile X syndrome market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Fragile X Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase Options Year End sale




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARATI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More
DEinternational Egypt

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

Read More
Gulf Excellent Group

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Read More
FS Corporation Inc.

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

Read More
Egyptian Industrial Investment Group

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

Read More
Vishnu Chemicals

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

Read More
MOUNT EVEREST BREWERIES LIMITED

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

Read More
Borges Branded Foods

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

Read More
Godrej Consumer Products Limited

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

Read More
ADC Therapeutics

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

Read More
Ivanti

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

Read More
Asiatic Electrical & Switchgear P. Ltd.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Read More
Denka Co., Ltd.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.

Read More